Bovine fusion antibodies
First Claim
1. An antibody fusion comprising:
- (a) a first antibody sequence;
(b) at least a portion of an ultralong complementarity determining region 3 (CDR3), wherein the portion of the ultralong CDR3 is 15 amino acids to 61 amino acids long; and
(c) a non-antibody sequence, wherein the non-antibody sequence is selected from a polypeptide selected from a group consisting of a Mamba1, a oxyntomodulin, a 550 peptide, an Amgen 1, and a parathyroid hormone;
wherein the portion of the ultralong CDR3 is fused or inserted into a hypervariable region of the first antibody sequence, and wherein the non-antibody sequence is fused or inserted into the portion of the ultralong CDR3.
2 Assignments
0 Petitions
Accused Products
Abstract
Disclosed herein are immunoglobulin constructs comprising at least one immunoglobulin domain or fragment thereof; and a therapeutic polypeptide or derivative or variant thereof attached to or inserted into said immunoglobulin domain. Also provided are immunoglobulin constructs comprising a mammalian immunoglobulin heavy chain comprising at least a portion of a knob domain in the complementarity-determining region 3 (CDR3H) or fragment thereof; and a therapeutic polypeptide attached to or inserted into said knob domain of the CDR3H. Also provided are immunoglobulin constructs comprising a mammalian immunoglobulin heavy chain comprising at least a portion of a stalk domain in the complementarity-determining region 3 (CDR3H) or fragment thereof; and a therapeutic polypeptide attached to or inserted into said stalk domain of the CDR3H. Also described herein are methods and compositions comprising the immunoglobulin constructs described herein for treatment and prevention of a disease or condition in a subject.
43 Citations
19 Claims
-
1. An antibody fusion comprising:
-
(a) a first antibody sequence; (b) at least a portion of an ultralong complementarity determining region 3 (CDR3), wherein the portion of the ultralong CDR3 is 15 amino acids to 61 amino acids long; and (c) a non-antibody sequence, wherein the non-antibody sequence is selected from a polypeptide selected from a group consisting of a Mamba1, a oxyntomodulin, a 550 peptide, an Amgen 1, and a parathyroid hormone; wherein the portion of the ultralong CDR3 is fused or inserted into a hypervariable region of the first antibody sequence, and wherein the non-antibody sequence is fused or inserted into the portion of the ultralong CDR3. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)
-
-
17. A vector comprising a polynucleotide comprising a sequence that is at least 90% homologous to SEQ ID NOs:
- 3-7 or a sequence that encodes for an amino acid that is at least 90% homologous to SEQ ID NOs;
10-14.
- 3-7 or a sequence that encodes for an amino acid that is at least 90% homologous to SEQ ID NOs;
-
18. A host cell comprising a polynucleotide comprising a sequence that is at least 90% homologous to SEQ ID NOs:
- 3-7 or expressing an amino acid that is at least 90% homologous to SEQ ID NOs;
10-14. - View Dependent Claims (19)
- 3-7 or expressing an amino acid that is at least 90% homologous to SEQ ID NOs;
Specification